RxDoctor Payments Data

Elena Barnes, MD

Rheumatology · Melbourne, FLNPI 1598731200

Payments from drug & device makers

$81,128in general payments, 2019–2025

Across 416 payments — averaging $195.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$77K
  • Amgen$970
  • Novartis$734
  • Pfizer$623
  • Johnson & Johnson$530
  • Lilly USA, LLC$335
  • plus $815 from 11 others

What the payments were for

  • Speaking & faculty fees$72,20089%
  • Travel & lodging$2,4683%
  • Food & beverage$6,3788%
  • Education$820%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$81,128 in reported general payments places this provider in the 75th percentile of 453 rheumatology providers in Florida.

See all rheumatology providers in Florida

Medicare billing

Part B allowed, 2024
$450,568
Medicare patients
1,366
Services billed
12,272

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept75$744,099
RinvoqUpadacitinib52$510,193
Humira(Cf) PenAdalimumab42$329,958
Humira PenAdalimumab38$303,824
XeljanzTofacitinib Citrate40$281,020
Skyrizi PenRisankizumab-Rzaa12$238,167
EnbrelEtanercept24$183,693
Humira(Cf)Adalimumab13$177,104
Xeljanz XrTofacitinib Citrate17$149,392
HumiraAdalimumab13$85,052
Actemra ActpenTocilizumab12$61,930
Hydroxychloroquine Sulfate500$32,398
MethotrexateMethotrexate Sodium451$20,877
Febuxostat69$11,416
Prednisone575$7,197

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Humira(Cf), Humira$77,122$772,34878 claims
PfizerXeljanz$623$281,02040 claims
AmgenEnbrel$970$183,69324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 453 rheumatology providers in Florida.

Other rheumatology in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →